CCM2 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "CCM2" in English language version.

Last modified: 04:19:26, 14 September 2026 (UTC)

Ref.Un. Ref.Website

Global rank English rank

1212nih.gov

5^th place

66doi.org

2^nd place

62ensembl.org

630^th place

326^th place

11semanticscholar.org

15^th place

8^th place

doi.org (Global: 2^nd place; English: 2^nd place)

Craig HD, Gunel M, Cepeda O, Johnson EW, Ptacek L, Steinberg GK, et al. (December 1998). "Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27". Human Molecular Genetics. 7 (12): 1851–1858. doi:10.1093/hmg/7.12.1851. PMID 9811928.
Uhlik MT, Abell AN, Johnson NL, Sun W, Cuevas BD, Lobel-Rice KE, et al. (December 2003). "Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock". Nature Cell Biology. 5 (12): 1104–1110. doi:10.1038/ncb1071. PMID 14634666. S2CID 1897773.
Zawistowski JS, Stalheim L, Uhlik MT, Abell AN, Ancrile BB, Johnson GL, et al. (September 2005). "CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis". Human Molecular Genetics. 14 (17): 2521–2531. doi:10.1093/hmg/ddi256. PMID 16037064.
Borikova AL, Dibble CF, Sciaky N, Welch CM, Abell AN, Bencharit S, et al. (April 2010). "Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype". The Journal of Biological Chemistry. 285 (16): 11760–11764. doi:10.1074/jbc.C109.097220. PMC 2852911. PMID 20181950.
Whitehead KJ, Chan AC, Navankasattusas S, Koh W, London NR, Ling J, et al. (February 2009). "The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases". Nature Medicine. 15 (2): 177–184. doi:10.1038/nm.1911. PMC 2767168. PMID 19151728.
Liquori CL, Berg MJ, Siegel AM, Huang E, Zawistowski JS, Stoffer T, et al. (December 2003). "Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations". American Journal of Human Genetics. 73 (6): 1459–1464. doi:10.1086/380314. PMC 1180409. PMID 14624391.

ensembl.org (Global: 630^th place; English: 326^th place)

may2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000136280 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000000378 – Ensembl, May 2017

nih.gov (Global: 5^th place; English: 5^th place)

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Entrez Gene: CCM2 cerebral cavernous malformation 2".
Borikova AL, Dibble CF, Sciaky N, Welch CM, Abell AN, Bencharit S, et al. (April 2010). "Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype". The Journal of Biological Chemistry. 285 (16): 11760–11764. doi:10.1074/jbc.C109.097220. PMC 2852911. PMID 20181950.
Whitehead KJ, Chan AC, Navankasattusas S, Koh W, London NR, Ling J, et al. (February 2009). "The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases". Nature Medicine. 15 (2): 177–184. doi:10.1038/nm.1911. PMC 2767168. PMID 19151728.
Liquori CL, Berg MJ, Siegel AM, Huang E, Zawistowski JS, Stoffer T, et al. (December 2003). "Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations". American Journal of Human Genetics. 73 (6): 1459–1464. doi:10.1086/380314. PMC 1180409. PMID 14624391.

pubmed.ncbi.nlm.nih.gov

Craig HD, Gunel M, Cepeda O, Johnson EW, Ptacek L, Steinberg GK, et al. (December 1998). "Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27". Human Molecular Genetics. 7 (12): 1851–1858. doi:10.1093/hmg/7.12.1851. PMID 9811928.
Uhlik MT, Abell AN, Johnson NL, Sun W, Cuevas BD, Lobel-Rice KE, et al. (December 2003). "Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock". Nature Cell Biology. 5 (12): 1104–1110. doi:10.1038/ncb1071. PMID 14634666. S2CID 1897773.
Zawistowski JS, Stalheim L, Uhlik MT, Abell AN, Ancrile BB, Johnson GL, et al. (September 2005). "CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis". Human Molecular Genetics. 14 (17): 2521–2531. doi:10.1093/hmg/ddi256. PMID 16037064.
Borikova AL, Dibble CF, Sciaky N, Welch CM, Abell AN, Bencharit S, et al. (April 2010). "Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype". The Journal of Biological Chemistry. 285 (16): 11760–11764. doi:10.1074/jbc.C109.097220. PMC 2852911. PMID 20181950.
Whitehead KJ, Chan AC, Navankasattusas S, Koh W, London NR, Ling J, et al. (February 2009). "The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases". Nature Medicine. 15 (2): 177–184. doi:10.1038/nm.1911. PMC 2767168. PMID 19151728.
Liquori CL, Berg MJ, Siegel AM, Huang E, Zawistowski JS, Stoffer T, et al. (December 2003). "Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations". American Journal of Human Genetics. 73 (6): 1459–1464. doi:10.1086/380314. PMC 1180409. PMID 14624391.

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Uhlik MT, Abell AN, Johnson NL, Sun W, Cuevas BD, Lobel-Rice KE, et al. (December 2003). "Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock". Nature Cell Biology. 5 (12): 1104–1110. doi:10.1038/ncb1071. PMID 14634666. S2CID 1897773.

CCM2 (English Wikipedia)

doi.org (Global: 2nd place; English: 2nd place)

ensembl.org (Global: 630th place; English: 326th place)